Paul J. Tiseo
Technik-/Wissenschafts-/F&E-Leiter bei COGNITION THERAPEUTICS, INC.
Profil
Paul J.
Tiseo is currently the Vice President-Clinical Development at Cognition Therapeutics, Inc. Prior to this, he worked as the Executive Director-Clinical Development at Centrexion Therapeutics Corp.
He completed his undergraduate degree at Stony Brook University and his doctorate at Lewis Katz School of Medicine.
Aktive Positionen von Paul J. Tiseo
| Unternehmen | Position | Beginn |
|---|---|---|
| COGNITION THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 11.10.2022 |
Ehemalige bekannte Positionen von Paul J. Tiseo
| Unternehmen | Position | Ende |
|---|---|---|
| CENTREXION THERAPEUTICS CORPORATION | Corporate Officer/Principal | - |
Ausbildung von Paul J. Tiseo
| Stony Brook University | Undergraduate Degree |
| Lewis Katz School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| COGNITION THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Centrexion Therapeutics Corp.
 Centrexion Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Centrexion Therapeutics Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, developing, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of chronic pain. Its product pipeline includes CNTX-4975, CNTX-0290, CNTX-6970, CNTX-2022, CNTX-6016, and intrathecal platform. The company was founded by Sol J. Barer and Jeffrey B. Kindler in February 2013 and is headquartered in Boston, MA. | Health Technology |
